ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016

USA Profile Username: jon@newsinnovations.com / edit profile ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016 PR Newswire LOS ANGELES, May 23, 2016 LOS ANGELES, May 23, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday, June 2, 2016 at 2:00 pm ET at the Grand Hyatt hotel, New York, New York.     To access the live audio webcast of the Marcum presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com. Contact: For ImmunoCellular Therapeutics, Ltd. Jane Green Investor Relations 415.348.0010 jane@jmgcomm.com  Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO   SOURCE ImmunoCellular Therapeutics, Ltd. Web Site: http://imuc.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504